Alnylam Pharmaceuticals
ALNY
#640
Rank
โ‚น2.670 T
Marketcap
โ‚น20,707
Share price
-0.59%
Change (1 day)
33.90%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : โ‚น354.13 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are โ‚น354.13 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31โ‚น337.20 B10%
2022-12-31โ‚น306.55 B34.81%
2021-12-31โ‚น227.39 B30.05%
2020-12-31โ‚น174.84 B156.36%
2019-12-31โ‚น68.20 B257.52%
2018-12-31โ‚น19.07 B30.87%
2017-12-31โ‚น14.57 B-37.39%
2016-12-31โ‚น23.28 B187.63%
2015-12-31โ‚น8.09 B-10.9%
2014-12-31โ‚น9.08 B-2.1%
2013-12-31โ‚น9.27 B10.42%
2012-12-31โ‚น8.40 B-3.1%
2011-12-31โ‚น8.67 B-17.66%
2010-12-31โ‚น10.53 B-25.19%
2009-12-31โ‚น14.07 B-16.92%
2008-12-31โ‚น16.94 B46.55%
2007-12-31โ‚น11.56 B572.29%
2006-12-31โ‚น1.71 B4.51%
2005-12-31โ‚น1.64 B90.32%
2004-12-31โ‚น0.86 B-69.32%
2003-12-31โ‚น2.81 B183.09%
2002-12-31โ‚น0.99 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
โ‚น80.51 B-77.26%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น688.80 B 94.50%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น201.89 B-42.99%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น72.36 B-79.57%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น0.59 B-99.83%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.099 T 1,339.91%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น5.163 T 1,358.14%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น3.002 T 747.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel